Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancerMasonic Cancer Center, University of Minnesota, MN, Minneapolis, United States.
University of Minnesota Genomics Center, University of Minnesota, MN, Minneapolis, United States.
Department of Computer Science, Princeton University, NJ, Princeton, United States.
Masonic Cancer Center, University of Minnesota, MN, Minneapolis, United States.
Masonic Cancer Center, University of Minnesota, MN, Minneapolis, United States.
Department of Human Oncology, University of Wisconsin-Madison, WI, Madison, United States; Carbone Cancer Center, University of Wisconsin-Madison, WI, Madison, United States; William S. Middleton Memorial Veterans Hospital Madison, WI, Madison, United States.
Departments of Radiation Oncology Urology, and Medicine, University of California San Francisco, CA, San Francisco, United States; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, CA, San Francisco, United States.
Department of Urology, University of Washington, WA, Seattle, United States.
Department of Urology, University of Washington, WA, Seattle, United States.
Minnesota Supercomputing Institute, University of Minnesota, MN, Minneapolis, United States.
Department of Computer Science, Princeton University, NJ, Princeton, United States.
Masonic Cancer Center, University of Minnesota, MN, Minneapolis, United States; Department of Laboratory Medicine and Pathology, University of Minnesota, MN, Minneapolis, United States; Department of Urology, University of Minnesota, MN, Minneapolis, United States.
Show others and affiliations
2023 (English)In: NAR Cancer, E-ISSN 2632-8674, Vol. 5, no 3, article id zcad045Article in journal (Refereed) Published
Abstract [en]
Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is unclear whether this reflects intercellular or intracellular heterogeneity of AR. Resolving this is important for developing new therapies and predictive biomarkers. Here, we analyzed 41 CRPC tumors and 6 patient-derived xenografts (PDXs) using linked-read DNA-sequencing, and identified 7 tumors that developed complex, multiply-rearranged AR gene structures in conjunction with very high AR copy number. Analysis of PDX models by optical genome mapping and fluorescence in situ hybridization showed that AR residing on extrachromosomal DNA (ecDNA) was an underlying mechanism, and was associated with elevated levels and diversity of AR expression. This study identifies co-evolution of AR gene copy number and structural complexity via ecDNA as a mechanism associated with endocrine therapy resistance.
Place, publisher, year, edition, pages
Oxford University Press, 2023. Vol. 5, no 3, article id zcad045
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-214514DOI: 10.1093/narcan/zcad045ISI: 001093643600001PubMedID: 37636316Scopus ID: 2-s2.0-85170407885OAI: oai:DiVA.org:umu-214514DiVA, id: diva2:1800628
Funder
Swedish Cancer Society, CAN 2018-863Swedish Research Council, 2018-025942023-09-272023-09-272025-04-24Bibliographically approved